The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction caused by deposition of amyloid light chain...

Descripción completa

Detalles Bibliográficos
Autor principal: Lousada, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523334/
https://www.ncbi.nlm.nih.gov/pubmed/32993758
http://dx.doi.org/10.1186/s13023-020-01525-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523334/
https://www.ncbi.nlm.nih.gov/pubmed/32993758
http://dx.doi.org/10.1186/s13023-020-01525-2

Ejemplares similares